SNY Sanofi

Regeneron and Sanofi (NASDAQ:SNY) announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the blockbuster therapy DUPIXENT. Under the agreement, Regeneron will contribute four long-acting, fully hu

The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.

Investing.com -- Shares of Sanofi jumped as much as 3.6% on Thursday before paring gains to trade 1.1% higher after the French drugmaker agreed to pay Regeneron $1 billion upfront and up to $7 billion in additional payments to expand their partnership on four long-acting medicines for inflammatory diseases.

The liquidation auctioneer Liquidity Services is closing in on a buy point. The stock is up roughly 45% this year.

GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.

The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.

SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.

Sanofi (ENXTPA:SAN) opened the Charles Best Building in Canada, described as the largest biomanufacturing investment in the country. The new Canadian site expands Sanofi's flu vaccine production capacity, with the goal of strengthening readiness for future influenza seasons. Sanofi agreed to transfer a portfolio of mature medicines and several manufacturing sites to Cheplapharm, while also taking an equity stake in the partner. The inauguration of the Charles Best Building and the broadened...

Amgen Inc (NASDAQ:AMGN, XETRA:AMG)'s price target was raised to $410 from $367 by Jefferies after dazodalibep delivered positive Phase 3 results in patients with systemic Sjögren's disease. Jefferies said the drug, a CD40L antagonist, achieved a statistically significant and clinically...

European equities traded in the US as American depositary receipts were tracking lower Wednesday mor

All the chairs of Europe’s big pharma companies have written a public letter asserting that a shift in strategy is needed to close the gap to international rivals.

The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.

Britain’s biggest pharmaceutical companies have warned the future of the industry is at risk as Europe loses ground to the US and China in medical research.

LONDON, Sept 22 (Reuters) - European drugmakers called for beefed-up government spending on medicines, faster trials and IP protections as they sounded warnings ‌on Tuesday that the continent's pharmaceutical industry risks losing out to the ‌United States and China. Cash-strapped European governments have been under pressure for some time from lobby groups ​and drugmakers to rethink how they attract, nurture, value and pay for innovative medicines to avoid falling behind in an increasingly com

Sanofi (NASDAQ:SNY) is reviewing its late-stage pipeline, broadening its business-development lens and working to rebuild early research output under new leadership, Chief Scientific Officer and Global Head of Research Mike Quigley said at a Bank of America event. Quigley said Chief Executive Offic

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s Global Healthcare Conference, with CEO and President Najat Khan emphasizing the company’s shift toward an end-to-end, AI-enabled drug discovery and development platform. Kha

Sanofi (NASDAQ:SNY) is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the company’s executive vice president and head of Specialty Care. Speaking at a Morgan Stanley fireside ch

Investing.com -- European assets may offer investors advantages that are being overlooked as markets remain heavily focused on U.S. technology leadership, according to Macquarie Global Strategy, which sees structural changes supporting stronger European returns.

Healthcare stocks were slightly lower late Wednesday afternoon, with the NYSE Healthcare Index fract

Earlier this month, Novavax participated in investor-focused healthcare conferences hosted by Citigroup and Cantor Fitzgerald in New York, outlining its vaccine and partnership positioning to a broad institutional audience. Around the same time, bipartisan lawmakers introduced the Protecting Approved Care Act, stirring concern across healthcare names like Novavax about potential changes to Medicare Advantage reimbursement practices and administrative requirements. We’ll now examine how...

Sanofi has delivered mixed returns over recent years, and with the share price around €75.43, the real issue for you is whether that level is justified by the earnings power the group is producing today. Over the past 3 years, the stock has declined about 14.8%, which puts the spotlight on whether the current valuation is still aligned with the profits the business is generating. The planned transfer of 20 mature medicines and three manufacturing sites to Cheplapharm, in exchange for a 26.4%...

Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm.

Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference. Marion McCourt, Regeneron’s EVP and head of commercial, said Dupixent’s growth

Healthcare stocks advanced Monday afternoon, with the NYSE Healthcare Index up 1.6% and the State St

Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo investor conference appearance. Ryan Crowe, senior vice president of investor relations and strategic ana

Novartis AG (NYSE:NVS) has reported the first major success from three closely watched pipeline programs expected to produce clinical data in 2026. Its oral drug remibrutinib outperformed Sanofi’s older multiple-sclerosis treatment teriflunomide in reducing relapses across two late-stage studies. The results strengthen remibrutinib’s case as a potential growth driver while Novartis (NYSE:NVS) faces generic pressure […]

Novavax (NASDAQ:NVAX) executives outlined the company’s transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi’s commercial rollout of NUVAXOVID, combination vaccine development and early

Novavax (NASDAQ:NVAX) outlined its strategy to expand the use of its Matrix-M adjuvant platform through licensing partnerships, internal research programs and commercialization alliances, with management highlighting progress in infectious disease vaccines and early oncology work at the Cantor Healt

LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.

Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last...

The oral drug remibrutinib cut relapse rates in patients with relapsing multiple sclerosis, beating a rival treatment in both studies

Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.

Novartis stock surged early Tuesday after its experimental multiple sclerosis treatment succeeded in a pair of midstage studies.

Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.

Novavax reported that partners Sanofi and Takeda have secured approvals for an updated Nuvaxovid formulation targeting the SARS-CoV-2 XFG variant for the 2026–2027 vaccination season across the U.S., European Union, Japan, and other major markets. These approvals allow Novavax to participate in the upcoming COVID-19 vaccination season primarily through royalties and milestones, while its partners shoulder the commercial execution and infrastructure burden. We'll now examine how Novavax’s...

Sanofi (ENXTPA:SAN) has permanently halted its Phase 3 RSV vaccine trial in infants and toddlers following a serious adverse event involving an infant death. The death was later linked to an underlying health condition that should have excluded the child from the study, prompting questions about trial screening procedures. The decision has drawn heightened regulatory attention, including Freedom of Information Act requests to the FDA, and raises concerns about RSV vaccine safety in very...

Novavax said Sanofi and Takeda received clearances for an updated Nuvaxovid formulation for the 2026-2027 COVID season.

Sanofi's stock trades above key moving averages as Dupixent and new drugs drive growth, while pipeline setbacks and vaccine weakness weigh.

European equities traded in the US as American depositary receipts were trending lower late Thursday

Amgen and AstraZeneca's drug, Tezspire, scored Thursday in an esophageal disease that affects an estimated 470,000 patients in the U.S.

New leaders at GSK, Novo Nordisk and Sanofi are taking the reins at pivotal moments for three of pharma’s largest companies.

The company has increased its dividend for 30 consecutive years.

NVAX stock surges amid biotech stock rally following Moderna and Merck cancer breakthrough.

The biggest names behind biotech stocks are investing richly in artificial intelligence with the goal of speeding up drug development.

Sanofi stock is coming off a mixed three year stretch, with the share price down about 10.5%, yet current valuation checks on earnings and cash flow multiples still suggest the shares lean toward the undervalued side rather than clearly expensive. Over the past three years Sanofi has delivered a share price decline of around 10.5%, which raises the question of whether the current price is better explained by softer expectations or by an opportunity in a stock that has lagged. Partnership...

Sanofi stock reaction to TD Cowen conference spotlight on immunology and rare diseases Sanofi (ENXTPA:SAN) is set to present at the TD Cowen Hot Wheels Tour in New York on 12 August 2026, with senior leaders highlighting its immunology, inflammation, and rare disease franchises. For investors watching Sanofi stock, the focus will be on how management frames the role of immunology and rare blood disorder development within its broader biopharma business, and what this might signal about...

European equities traded in the US as American depositary receipts were trending lower in late Tuesd

Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Tayl

As a flood of debt sales by US tech companies ripples through the credit market, it seems to be triggering an inadvertent rise in risk metrics for some of the world’s safest firms.